Image from Google Jackets

PIPAC : Pressurized IntraPeritoneal Aerosol Chemotherapy - Cancer under Pressure. [E-Book]

By: Contributor(s): Publication details: Berlin/Boston : De Gruyter, 2014.Description: 1 online resource (252 pages)Content type:
  • text
Media type:
  • computer
Carrier type:
  • online resource
ISBN:
  • 9783110366624
  • 3110366622
  • 9783110386363
  • 3110386364
  • 3110366614
  • 9783110366617
Subject(s): NLM classification:
  • QZ 267
Other classification:
  • 610
Online resources:
Contents:
Preface; Acknowledgments; 1 Introduction; 2 Peritoneal carcinomatosis: a neglected disease; 2.1 An unmet medical need; 2.2 Role of the physician in provision of care in advanced peritoneal cancer; 2.3 Palliative care in peritoneal carcinomatosis; 3 Normal and diseased peritoneum; 3.1 Ontology; 3.2 Anatomy; 3.2.1 Blood supply; 3.2.2 Lymphatics; 3.2.3 Lymphatic stomata; 3.2.4 Milky spots; 3.2.5 Greater omentum; 3.2.6 Peritoneal nerves; 3.3 Physiology of peritoneum; 3.3.1 Peritoneum-plasma barrier; 3.3.2 Intraperitoneal Hydrostatic Pressure; 3.4 Pathophysiology of peritoneal carcinomatosis.
3.4.1 Epithelial-mesenchymal transition3.4.2 Interstitial intratumoral fluid pressure; 3.4.3 Ascites; 3.4.4 Hormonal changes; 4 Diagnosis and staging of peritoneal carcinomatosis; 4.1 Diagnostic workup; 4.2 Imaging studies; 4.2.1 Computer tomography (CT scan); 4.2.2 Magnetic Resonance Imaging (MRI); 4.2.3 Ultrasound; 4.2.4 FDG-Positron emission tomography (PET); 4.3 Diagnostic laparoscopy; 4.3.1 Peritoneal Cancer Index; 4.4 Peritoneal or pleural cytology; 4.4.1 Gastric cancer; 4.4.2 Ovarian cancer; 4.4.3 Colorectal cancer; 5 Therapy of peritoneal carcinomatosis.
5.1 Systemic palliative chemotherapy5.2 Intraperitoneal chemotherapy; 5.3 Drug uptake into tumoral tissue; 5.3.1 Diffusion; 5.3.2 Convection; 5.4 Effect of peritonectomy on drug clearance; 5.5 Influence of intraperitoneal drug concentration; 5.6 Tissue penetration of various drugs; 5.6.1 Doxorubicin (see also page 199); 5.6.2 Cisplatinum (see also page 198); 5.6.3 Oxaliplatinum; 5.6.4 Taxanes (Paclitaxel, Docetaxel); 5.7 Perioperative intraperitoneal chemotherapy; 5.7.1 CHPP; 5.7.2 NIPS; 5.7.3 EIPL; 5.7.4 EPIC; 5.8 Intraperitoneal chemotherapy for ascites.
5.9 Limitations of intraperitoneal chemotherapy5.9.1 Poor drug penetration; 5.9.2 Poor surface exposition; 5.9.3 Local toxicity; 5.9.4 Peritoneal sclerosis; 5.10 Intraperitoneal immunotherapy; 5.10.1 Catumaxomab; 5.10.2 Bevacizumab; 5.10.3 Immunoradiotherapy; 5.11 Intraperitoneal cytolytic virotherapy; 5.12 Nanodrugs; 5.13 Combined CRS with HIPEC; 5.13.1 Cytoreductive surgery (CRS); 5.13.2 Hyperthermic IntraPEritoneal Chemotherapy (HIPEC); 5.13.3 Colorectal cancer; 5.13.4 Ovarian Cancer; 5.13.5 Gastric Cancer; 5.13.6 Learning curve and expertise; 5.13.7 Evidence of cost effectiveness.
5.13.8 Safety5.13.9 Indications for CRS and HIPEC; 6 Assessing tumor response in peritoneal carcinomatosis; 6.1 Natural history of peritoneal carcinomatosis; 6.2 RECIST criteria; 6.2.1 RECIST criteria in peritoneal carcinomatosis; 6.3 Laparoscopy in peritoneal carcinomatosis; 6.4 Histology for determining tumor response; 6.5 Tumor markers for determining tumor response; 6.5.1 Gastric cancer; 6.5.2 Ovarian cancer; 6.5.3 Colorectal cancer; 6.6 Determining clinical benefit rate in peritoneal carcinomatosis; 7 Principle of therapeutic capnoperitoneum; 7.1 Material and methods.
7.1.1 Design of the prototype.
Summary: <!Doctype html public ""-//w3c//dtd html 4.0 transitional//en""> <html><head> <meta content=""text/html; charset=iso-8859-1"" http-equiv=content-type> <meta name=generator content=""mshtml 8.00.6001.23543""></head> <body> Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a novel approach for treating peritoneal carcinomatosis. First encouraging results have been obtained in human patients. </body></html>
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Home library Class number URL Status Date due Barcode
Electronic book Stenhouse Library Link to resource Available

Print version record.

Preface; Acknowledgments; 1 Introduction; 2 Peritoneal carcinomatosis: a neglected disease; 2.1 An unmet medical need; 2.2 Role of the physician in provision of care in advanced peritoneal cancer; 2.3 Palliative care in peritoneal carcinomatosis; 3 Normal and diseased peritoneum; 3.1 Ontology; 3.2 Anatomy; 3.2.1 Blood supply; 3.2.2 Lymphatics; 3.2.3 Lymphatic stomata; 3.2.4 Milky spots; 3.2.5 Greater omentum; 3.2.6 Peritoneal nerves; 3.3 Physiology of peritoneum; 3.3.1 Peritoneum-plasma barrier; 3.3.2 Intraperitoneal Hydrostatic Pressure; 3.4 Pathophysiology of peritoneal carcinomatosis.

3.4.1 Epithelial-mesenchymal transition3.4.2 Interstitial intratumoral fluid pressure; 3.4.3 Ascites; 3.4.4 Hormonal changes; 4 Diagnosis and staging of peritoneal carcinomatosis; 4.1 Diagnostic workup; 4.2 Imaging studies; 4.2.1 Computer tomography (CT scan); 4.2.2 Magnetic Resonance Imaging (MRI); 4.2.3 Ultrasound; 4.2.4 FDG-Positron emission tomography (PET); 4.3 Diagnostic laparoscopy; 4.3.1 Peritoneal Cancer Index; 4.4 Peritoneal or pleural cytology; 4.4.1 Gastric cancer; 4.4.2 Ovarian cancer; 4.4.3 Colorectal cancer; 5 Therapy of peritoneal carcinomatosis.

5.1 Systemic palliative chemotherapy5.2 Intraperitoneal chemotherapy; 5.3 Drug uptake into tumoral tissue; 5.3.1 Diffusion; 5.3.2 Convection; 5.4 Effect of peritonectomy on drug clearance; 5.5 Influence of intraperitoneal drug concentration; 5.6 Tissue penetration of various drugs; 5.6.1 Doxorubicin (see also page 199); 5.6.2 Cisplatinum (see also page 198); 5.6.3 Oxaliplatinum; 5.6.4 Taxanes (Paclitaxel, Docetaxel); 5.7 Perioperative intraperitoneal chemotherapy; 5.7.1 CHPP; 5.7.2 NIPS; 5.7.3 EIPL; 5.7.4 EPIC; 5.8 Intraperitoneal chemotherapy for ascites.

5.9 Limitations of intraperitoneal chemotherapy5.9.1 Poor drug penetration; 5.9.2 Poor surface exposition; 5.9.3 Local toxicity; 5.9.4 Peritoneal sclerosis; 5.10 Intraperitoneal immunotherapy; 5.10.1 Catumaxomab; 5.10.2 Bevacizumab; 5.10.3 Immunoradiotherapy; 5.11 Intraperitoneal cytolytic virotherapy; 5.12 Nanodrugs; 5.13 Combined CRS with HIPEC; 5.13.1 Cytoreductive surgery (CRS); 5.13.2 Hyperthermic IntraPEritoneal Chemotherapy (HIPEC); 5.13.3 Colorectal cancer; 5.13.4 Ovarian Cancer; 5.13.5 Gastric Cancer; 5.13.6 Learning curve and expertise; 5.13.7 Evidence of cost effectiveness.

5.13.8 Safety5.13.9 Indications for CRS and HIPEC; 6 Assessing tumor response in peritoneal carcinomatosis; 6.1 Natural history of peritoneal carcinomatosis; 6.2 RECIST criteria; 6.2.1 RECIST criteria in peritoneal carcinomatosis; 6.3 Laparoscopy in peritoneal carcinomatosis; 6.4 Histology for determining tumor response; 6.5 Tumor markers for determining tumor response; 6.5.1 Gastric cancer; 6.5.2 Ovarian cancer; 6.5.3 Colorectal cancer; 6.6 Determining clinical benefit rate in peritoneal carcinomatosis; 7 Principle of therapeutic capnoperitoneum; 7.1 Material and methods.

7.1.1 Design of the prototype.

<!Doctype html public ""-//w3c//dtd html 4.0 transitional//en""> <html><head> <meta content=""text/html; charset=iso-8859-1"" http-equiv=content-type> <meta name=generator content=""mshtml 8.00.6001.23543""></head> <body> Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a novel approach for treating peritoneal carcinomatosis. First encouraging results have been obtained in human patients. </body></html>

Includes bibliographical references at the end of each chapters and index.

In English.

Added to collection customer.56279.3 - Master record variable field(s) change: 082

There are no comments on this title.

to post a comment.
London Health Libraries Koha Consortium privacy notice